The field of diabetes cell and gene therapy exhibits a development landscape where the United States and China possess distinct advantages: 1. The United States maintains leadership in original technology. 2. China holds advantages in the speed of clinical translation and patient resources. 3. International cooperation and complementarity are key for the future.